Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial

Jonathan A. Ledermann, Alain Lortholary, Richard T. Penson, Rebecca Asher, Val Gebski, Diane Provencher, Ilan Bruchim, Tomasz Huzarski, Maria Pilar Barretina-Ginesta, Stefania Pipitone, Linda Mileshkin, Nicoletta Colombo, Tjoung-Won Park-Simon, Koji Matsumoto, Ingrid Boere, Olga Mikheeva, Jae-Weon Kim, Gustavo Girotto, Ignace Vergote, Dave Carter, Elizabeth S. Lowe, Eric Pujade-Lauraine

Open source

DOI: 10.1016/j.ijgc.2026.104556
Published: 2026-05
Container: International Journal of Gynecological Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2026.104556,
  title = {Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial},
  author = {Jonathan A. Ledermann and Alain Lortholary and Richard T. Penson and Rebecca Asher and Val Gebski and Diane Provencher and Ilan Bruchim and Tomasz Huzarski and Maria Pilar Barretina-Ginesta and Stefania Pipitone and Linda Mileshkin and Nicoletta Colombo and Tjoung-Won Park-Simon and Koji Matsumoto and Ingrid Boere and Olga Mikheeva and Jae-Weon Kim and Gustavo Girotto and Ignace Vergote and Dave Carter and Elizabeth S. Lowe and Eric Pujade-Lauraine},
  year = {2026},
  journal = {International Journal of Gynecological Cancer},
  doi = {10.1016/j.ijgc.2026.104556},
  url = {https://doi.org/10.1016/j.ijgc.2026.104556}
}

RIS

TY  - JOUR
TI  - Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
AU  - Jonathan A. Ledermann
AU  - Alain Lortholary
AU  - Richard T. Penson
AU  - Rebecca Asher
AU  - Val Gebski
AU  - Diane Provencher
AU  - Ilan Bruchim
AU  - Tomasz Huzarski
AU  - Maria Pilar Barretina-Ginesta
AU  - Stefania Pipitone
AU  - Linda Mileshkin
AU  - Nicoletta Colombo
AU  - Tjoung-Won Park-Simon
AU  - Koji Matsumoto
AU  - Ingrid Boere
AU  - Olga Mikheeva
AU  - Jae-Weon Kim
AU  - Gustavo Girotto
AU  - Ignace Vergote
AU  - Dave Carter
AU  - Elizabeth S. Lowe
AU  - Eric Pujade-Lauraine
PY  - 2026
JO  - International Journal of Gynecological Cancer
DO  - 10.1016/j.ijgc.2026.104556
UR  - https://doi.org/10.1016/j.ijgc.2026.104556
ER  -

APA

Ledermann, J. A., Lortholary, A., Penson, R. T., Asher, R., Gebski, V., Provencher, D., Bruchim, I., Huzarski, T., Barretina-Ginesta, M. P., Pipitone, S., Mileshkin, L., Colombo, N., Park-Simon, T., Matsumoto, K., Boere, I., Mikheeva, O., Kim, J., Girotto, G., Vergote, I., Carter, D., Lowe, E. S., & Pujade-Lauraine, E. (2026). Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2026.104556

Source records

crossref · retrieved 2026-09-26T11:15:21.140Z